PDF(Pubmed)
Abstract：
BACKGROUND: Testosterone replacement therapy (TRT) can improve quality of life for men with hypogonadism. However, it is generally avoided in patients with a history of prostate cancer or breast cancer as there is uncertainty about risks. This case illustrates an example of synchronous metastatic prostate cancer and male breast cancer following TRT.
METHODS: A 72-year-old man with previously treated intermediate-risk prostate adenocarcinoma experienced a gradual rise in prostate-specific antigen (PSA) while self-administering testosterone replacement. He was later found to have recurrent metastatic prostate cancer and prior to initiating androgen deprivation therapy (ADT), he was also diagnosed with male breast cancer. His treatment has consisted of continued ADT for metastatic castration-sensitive prostate cancer (mCSPC) as well as surgical resection of his breast cancer.
CONCLUSIONS: ADT plays a role in treatment of male breast cancer and prostate cancer. TRT remains relatively contraindicated in patients with a history of these malignancies, but the evidence supporting this recommendation is somewhat limited.
CONCLUSIONS: This case highlights the potential risk for synchronous recurrent prostate and new male breast cancer following TRT. Further studies are needed to better elucidate the increased risks of these malignancies with TRT.
METHODS: A 72-year-old man with previously treated intermediate-risk prostate adenocarcinoma experienced a gradual rise in prostate-specific antigen (PSA) while self-administering testosterone replacement. He was later found to have recurrent metastatic prostate cancer and prior to initiating androgen deprivation therapy (ADT), he was also diagnosed with male breast cancer. His treatment has consisted of continued ADT for metastatic castration-sensitive prostate cancer (mCSPC) as well as surgical resection of his breast cancer.
CONCLUSIONS: ADT plays a role in treatment of male breast cancer and prostate cancer. TRT remains relatively contraindicated in patients with a history of these malignancies, but the evidence supporting this recommendation is somewhat limited.
CONCLUSIONS: This case highlights the potential risk for synchronous recurrent prostate and new male breast cancer following TRT. Further studies are needed to better elucidate the increased risks of these malignancies with TRT.
摘要：
背景：睾酮替代疗法（TRT）可以改善性腺功能减退症男性的生活质量。然而,在有前列腺癌或乳腺癌病史的患者中，由于风险存在不确定性，因此通常避免使用这种疾病。该病例说明了TRT后同步转移性前列腺癌和男性乳腺癌的例子。
方法：一名72岁男性曾接受过治疗的中危前列腺腺癌患者在自我给予睾酮替代治疗时，前列腺特异性抗原（PSA）逐渐升高。后来发现他患有复发性转移性前列腺癌，并且在开始雄激素剥夺治疗（ADT）之前，他还被诊断出患有男性乳腺癌。他的治疗包括继续ADT治疗转移性去势敏感性前列腺癌（mCSPC）以及手术切除乳腺癌。
结论：ADT在男性乳腺癌和前列腺癌的治疗中起作用。TRT在有这些恶性肿瘤病史的患者中仍然相对禁忌，但支持这一建议的证据有限.
结论：该病例强调了TRT后同步前列腺复发和新发男性乳腺癌的潜在风险。需要进一步的研究来更好地阐明这些恶性肿瘤与TRT的风险增加。
方法：一名72岁男性曾接受过治疗的中危前列腺腺癌患者在自我给予睾酮替代治疗时，前列腺特异性抗原（PSA）逐渐升高。后来发现他患有复发性转移性前列腺癌，并且在开始雄激素剥夺治疗（ADT）之前，他还被诊断出患有男性乳腺癌。他的治疗包括继续ADT治疗转移性去势敏感性前列腺癌（mCSPC）以及手术切除乳腺癌。
结论：ADT在男性乳腺癌和前列腺癌的治疗中起作用。TRT在有这些恶性肿瘤病史的患者中仍然相对禁忌，但支持这一建议的证据有限.
结论：该病例强调了TRT后同步前列腺复发和新发男性乳腺癌的潜在风险。需要进一步的研究来更好地阐明这些恶性肿瘤与TRT的风险增加。
